Citigroup recorded Amgen Inc. (NASDAQ:AMGN), cutting its target to $172.00 today
- Updated: September 28, 2016
In a report issued 9/28/2016 Citigroup lowered the target price of Amgen Inc. (NASDAQ:AMGN) from $175.00 to $172.00 stating a potential upside of 0.01%.
Yesterday Amgen Inc. (NASDAQ:AMGN) traded -0.61% lower at $170.72. The company’s 50-day moving average is $172.07 and its 200-day moving average is $160.76. The last stock close price is up 6.11% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 401,154 shares of Amgen Inc. traded hands, down from an average trading volume of 2,857,300
Recent Performance Chart
Amgen Inc. has 52 week low of $135.64 and a 52 week high of $176.85 with a PE ratio of 17.46 and has a market capitalization of $0.
Also covering Amgen Inc.'s target, a total of 17 brokerages have issued a ratings update on Amgen Inc.. The 12-month price target is $183.88 with 2 brokers rating the stock a strong buy, 9 firms rating the stock a buy, ten brokerages rating the stock a hold, 0 analysts rating the company a underperform, and lastly 0 brokers rating the stock a sell.
Brief Synopsis On Amgen Inc. (NASDAQ:AMGN)
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company's business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Company focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. Its products in Phase III programs include Aranesp for Myelodysplastic syndromes; ENBREL for Psoriatic arthritis and Rheumatoid arthritis remission; IMLYGIC for Metastatic melanoma, and Kyprolis for Multiple myeloma.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.